Skip to Main Content

INFORMATION FOR

Christopher Tormey, MD

Professor of Laboratory Medicine; Director, Transfusion Medicine Service, Laboratory Medicine; Director, Transfusion Medicine Fellowship, Laboratory Medicine

Contact Information

Christopher Tormey, MD

Office Location

Mailing Address

  • Laboratory Medicine

    PO Box 208035

    New Haven, CT 06520-8035

    United States

Research Summary

Dr. Tormey has several diverse research interests within the fields of Transfusion Medicine & Laboratory Hematology ranging from large clinical studies to translational research projects. Areas of current investigation include blood bank-based immunohematology where the properties of red blood cell alloantibodies in veteran populations are examined, particularly those factors influencing the duration of humoral response following alloimmunization. In addition, Dr. Tormey is interested in studying the biochemical and immunologic effects of storage on platelet components in the blood bank. Finally, he is also interested in studying coagulation assays, in particular the clinical scenarios leading to discrepant coagulation test results and the general impact of coagulation assays on transfusion-related care.

Coauthors

Research Interests

Blood Coagulation Tests; Blood Group Incompatibility; Blood Group Antigens; Blood Platelet Disorders; Platelet Function Tests; Health Care

Selected Publications

  • SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell AlloimmunizationGuarente J, Hendrickson J, Li F, Parziale S, Tormey C, Siddon A. SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell Alloimmunization Blood 2022, 140: 5706-5707. DOI: 10.1182/blood-2022-169888.
  • Recent RhIG Administration Does Not Interfere with the Rosette TestZheng L, Tormey C, Guarente J. Recent RhIG Administration Does Not Interfere with the Rosette Test American Journal Of Clinical Pathology 2022, 158: s159-s159. DOI: 10.1093/ajcp/aqac126.338.
  • Platelet production and kineticsBinns T, Tormey C, Rinder H. Platelet production and kinetics 2022, 158-167. DOI: 10.1002/9781119719809.ch15.
  • Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuriaTormey C, Siddon A. Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria 2022, 346-363. DOI: 10.1002/9781119719809.ch31.
  • Transfusion in Benign Haematological DiseaseSalazar E, Tormey C. Transfusion in Benign Haematological Disease 2022, 399-408. DOI: 10.1002/9781119665885.ch33.
  • Plasma products for transfusion: an overviewHorstman E, Tormey C. Plasma products for transfusion: an overview Annals Of Blood 2022, 0: 0-0. DOI: 10.21037/aob-22-7.
  • Renal allograft rejection with thrombotic microangiopathy associated with a Kidd blood group system alloantibodyLee E, McHenry A, Siddon A, Tormey C. Renal allograft rejection with thrombotic microangiopathy associated with a Kidd blood group system alloantibody American Journal Of Clinical Pathology 2021, 156: s159-s160. DOI: 10.1093/ajcp/aqab191.340.
  • Comparison of Polybrene DAT and Conventional DAT in Cases of Suspected DAT Negative Autoimmune Hemolytic Anemia (AIHA)Sultana S, Balbuena-Marle R, Tormey C, Gollan J, Skeret R. Comparison of Polybrene DAT and Conventional DAT in Cases of Suspected DAT Negative Autoimmune Hemolytic Anemia (AIHA) American Journal Of Clinical Pathology 2021, 156: s160-s161. DOI: 10.1093/ajcp/aqab191.342.
  • Single institution retrospective review of CD34+ apheresis collection based on mobilization regimen and primary diagnosisPuzo C, Li P, Siddon A, Tormey C. Single institution retrospective review of CD34+ apheresis collection based on mobilization regimen and primary diagnosis American Journal Of Clinical Pathology 2021, 156: s161-s162. DOI: 10.1093/ajcp/aqab191.345.
  • Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System ExperienceBrowning S, Gormally M, Briggs N, Li M, Zakko A, Laurent-Rolle M, Ladines-Lim J, Morrison A, Kandel P, Khan M, McLeod G, Buller G, Owusu K, Treggiari M, Hendrickson J, Tormey C, Desruisseaux M. Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience Blood 2020, 136: 39-40. PMCID: PMC8330251, DOI: 10.1182/blood-2020-137352.
  • Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic PurpuraGoshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.
  • Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell CollectionGupta G, Perreault S, Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection Blood 2020, 136: 41-41. DOI: 10.1182/blood-2020-140171.
  • Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV DeficiencyGupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.
  • Reliability of the Dilute Russel Viper Venom Time (dRVVT) in Determining Lupus Anticoagulant (LAC) in Anticoagulated PatientsKhan W, Rinder H, Tormey C, Siddon A. Reliability of the Dilute Russel Viper Venom Time (dRVVT) in Determining Lupus Anticoagulant (LAC) in Anticoagulated Patients American Journal Of Clinical Pathology 2020, 154: s11-s12. DOI: 10.1093/ajcp/aqaa137.020.
  • Co-Culture of Acinetobacter calcoaceticus-baumannii complex and Staphylococcus saprophyticus Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related SepsisKerantzas C, Merwede J, Snyder E, Hendrickson J, Tormey C, Kazmierczak B, Peaper D. Co-Culture of Acinetobacter calcoaceticus-baumannii complex and Staphylococcus saprophyticus Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related Sepsis American Journal Of Clinical Pathology 2020, 154: s14-s14. DOI: 10.1093/ajcp/aqaa137.025.
  • Hemoglobin C/Korle-Bu Identified In A Patient With A Previous Diagnosis Of Hemoglobin S/C DiseaseDolezal D, Tormey C, Rinder H, Siddon A. Hemoglobin C/Korle-Bu Identified In A Patient With A Previous Diagnosis Of Hemoglobin S/C Disease American Journal Of Clinical Pathology 2020, 154: s110-s111. DOI: 10.1093/ajcp/aqaa161.242.
  • Passive Transfer Of Allo-Antibodies Following Rhig Administration Given For Rh-Mismatched Platelets ProphylaxisSostin N, Hendrickson J, Balbuena-Merle R, Tormey C. Passive Transfer Of Allo-Antibodies Following Rhig Administration Given For Rh-Mismatched Platelets Prophylaxis American Journal Of Clinical Pathology 2020, 154: s158-s159. DOI: 10.1093/ajcp/aqaa161.346.
  • Chapter 1 A Focused Review of Basic Immunology ConceptsBaine I, Tormey C. Chapter 1 A Focused Review of Basic Immunology Concepts 2020, 1-14. DOI: 10.1016/b978-0-323-67509-3.00001-9.
  • Chapter 2 Methods of RBC Alloimmunization to ABO and Non-ABO Antigens, and Test MethodologiesStendahl K, Tormey C, Baine I. Chapter 2 Methods of RBC Alloimmunization to ABO and Non-ABO Antigens, and Test Methodologies 2020, 15-33. DOI: 10.1016/b978-0-323-67509-3.00002-0.
  • Clinical Utility of B- and T-Cell Gene Rearrangement Studies in Blood and Bone Marrow SamplesMendoza H, Tormey C, Siddon A. Clinical Utility of B- and T-Cell Gene Rearrangement Studies in Blood and Bone Marrow Samples Blood 2019, 134: 5223-5223. DOI: 10.1182/blood-2019-121747.
  • The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood DonorsBalbuena-Merle R, Hauser R, Karafin M, Tan S, Spencer B, Roubinian N, Wu Y, Triulzi D, Kleinman S, Gottschall J, Tormey C, Hendrickson J. The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors Blood 2019, 134: 2452-2452. DOI: 10.1182/blood-2019-121388.
  • PT and aPTT Are Not Predictors of Thromboembolic EventsShervinrad M, Tormey C, Siddon A. PT and aPTT Are Not Predictors of Thromboembolic Events American Journal Of Clinical Pathology 2019, 152: s36-s36. DOI: 10.1093/ajcp/aqz112.068.
  • Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic VariantsGu S, Shevell L, Tormey C, Rinder H, Lee A. Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic Variants American Journal Of Clinical Pathology 2019, 152: s35-s35. DOI: 10.1093/ajcp/aqz112.066.
  • Evaluation of Positive T- and B-Cell Gene Rearrangement Studies Among Patients Without a Definitive Diagnosis by Other AssaysMendoza H, Tormey C, Siddon A. Evaluation of Positive T- and B-Cell Gene Rearrangement Studies Among Patients Without a Definitive Diagnosis by Other Assays American Journal Of Clinical Pathology 2019, 152: s35-s36. DOI: 10.1093/ajcp/aqz112.067.
  • Chapter 57 Platelet Transfusion Refractory PatientsTormey C, Hendrickson J. Chapter 57 Platelet Transfusion Refractory Patients 2019, 361-364. DOI: 10.1016/b978-0-12-813726-0.00057-x.
  • 64 Platelet Transfusion MedicineSiddon A, Tormey C, Snyder E. 64 Platelet Transfusion Medicine 2019, 1137-1159. DOI: 10.1016/b978-0-12-813456-6.00064-3.
  • Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic NeutropeniaChang E, Tormey C, Siddon A, Rahmani M, Wong E. Duffy Antigen Phenotyping Is a Useful and Clinically Available Test for Benign Ethnic Neutropenia Blood 2018, 132: 2546-2546. DOI: 10.1182/blood-2018-99-117178.
  • Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic PurpuraGoshua G, Gokhale A, Hendrickson J, Tormey C, Lee A. Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura Blood 2018, 132: 3814-3814. DOI: 10.1182/blood-2018-99-113621.
  • The Development and Implementation of a Novel Electronic Consult (E-Consult) System by a Laboratory Medicine Service: Experience From the First 2 Years of UseStendahl K, Siddon A, Peaper D, Hauser R, Campbell S, Tormey C. The Development and Implementation of a Novel Electronic Consult (E-Consult) System by a Laboratory Medicine Service: Experience From the First 2 Years of Use American Journal Of Clinical Pathology 2018, 150: s134-s134. DOI: 10.1093/ajcp/aqy103.320.
  • Transfusion Medicine Equations Made Internet AccessibleCharifa A, Ryder A, Cheng C, Tormey C, Hauser R. Transfusion Medicine Equations Made Internet Accessible American Journal Of Clinical Pathology 2018, 150: s141-s141. DOI: 10.1093/ajcp/aqy105.336.
  • Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host DiseaseSiddon A, Tormey C. Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease 2018, 105-117. DOI: 10.1007/978-3-319-89866-7_7.
  • 60 The Application of Sigma Metrics in Screening for HIV and HCVBaine I, Bahar B, Tormey C. 60 The Application of Sigma Metrics in Screening for HIV and HCV American Journal Of Clinical Pathology 2018, 149: s26-s26. DOI: 10.1093/ajcp/aqx116.059.
  • 326 Assessing the Correlation Between SF3B1 Variants and Ring Sideroblasts Percentage in Patients With Myeloid Neoplasm Undergoing Next-Generation SequencingBalbuena-Merle R, Howe J, Hager K, Hager K, Torres R, Rinder H, Tormey C, Siddon A. 326 Assessing the Correlation Between SF3B1 Variants and Ring Sideroblasts Percentage in Patients With Myeloid Neoplasm Undergoing Next-Generation Sequencing American Journal Of Clinical Pathology 2018, 149: s140-s141. DOI: 10.1093/ajcp/aqx127.325.
  • Chapter 21 Data Interpretation in Laboratory MedicineTormey C, Gehrie E, Pham H, Bucy R, Lorenz R, Zheng X, Hendrickson J. Chapter 21 Data Interpretation in Laboratory Medicine 2018, 489-510. DOI: 10.1016/b978-0-12-803999-1.00021-3.
  • Chapter 7 Noninfectious Complications of Transfusion Adverse EventsRutter S, Tormey C, Gokhale A. Chapter 7 Noninfectious Complications of Transfusion Adverse Events 2018, 69-84. DOI: 10.1016/b978-0-323-54458-0.00007-6.
  • Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen AlloimmunizationBaine I, Hendrickson J, Tormey C. Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization 2018, 25-39. DOI: 10.1016/b978-0-323-54458-0.00004-0.
  • Discordance Between Functional Screening and Genetic Confirmatory Diagnostic Tests: A Retrospective Analysis of Activated Protein C Resistance and Factor 5 Leiden Testing Over a 5-Year PeriodBaraban E, Siddon A, Tormey C. Discordance Between Functional Screening and Genetic Confirmatory Diagnostic Tests: A Retrospective Analysis of Activated Protein C Resistance and Factor 5 Leiden Testing Over a 5-Year Period American Journal Of Clinical Pathology 2017, 147: s160-s161. DOI: 10.1093/ajcp/aqw191.019.
  • Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic MalignanciesAsare M, Hendrickson J, Tormey C. Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies Blood 2016, 128: 1463-1463. DOI: 10.1182/blood.v128.22.1463.1463.
  • Daratumumab Interferes with Flow Cytometric Evaluation of Multiple MyelomaPerincheri S, Torres R, Tormey C, Smith B, Rinder H, Siddon A. Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma Blood 2016, 128: 5630-5630. DOI: 10.1182/blood.v128.22.5630.5630.
  • A Modified Approach to Fibrinogen Replacement in the Setting of DysfibrinogenemiaChandler J, Bahel P, Siddon A, Torres R, Rinder H, Tormey C. A Modified Approach to Fibrinogen Replacement in the Setting of Dysfibrinogenemia American Journal Of Clinical Pathology 2016, 146 DOI: 10.1093/ajcp/aqw160.005.
  • Antiphospholipid Antibodies and Risk for Thrombosis in the Veteran PopulationWilson P, Tormey C. Antiphospholipid Antibodies and Risk for Thrombosis in the Veteran Population American Journal Of Clinical Pathology 2016, 146 DOI: 10.1093/ajcp/aqw164.017.
  • Transfusion MedicineHendrickson J, Tormey C. Transfusion Medicine Hematology/Oncology Clinics Of North America 2016, 30: i. DOI: 10.1016/s0889-8588(16)30041-7.
  • Platelet production and kineticsTormey C, Rinder H. Platelet production and kinetics 2016, 206-214. DOI: 10.1002/9781119013020.ch17.
  • Impact of Molecular Clonality on Survival in Acute Myeloid LeukemiaSchulz W, Durant T, Rinder H, Tormey C, Torres R, Smith B, Hager K, Hager K, Howe J, Siddon A. Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia Blood 2015, 126: 1385-1385. DOI: 10.1182/blood.v126.23.1385.1385.
  • A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC AlloimmunizationCelli R, Schulz W, Hendrickson J, Tormey C. A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization Blood 2015, 126: 2349-2349. DOI: 10.1182/blood.v126.23.2349.2349.
  • Examining Discrepancies in Results Between Ristocetin-Induced Platelet Agglutination and Ristocetin Cofactor ActivityDesai D, Tormey C, Rinder H, Siddon A. Examining Discrepancies in Results Between Ristocetin-Induced Platelet Agglutination and Ristocetin Cofactor Activity American Journal Of Clinical Pathology 2015, 144: a030-a030. DOI: 10.1093/ajcp/144.suppl2.030.
  • Role of Anti-Cyclic Citrullinated Peptide Screening in Patients With Lung Disease but Without Connective Tissue DisordersSchulz W, Tormey C. Role of Anti-Cyclic Citrullinated Peptide Screening in Patients With Lung Disease but Without Connective Tissue Disorders American Journal Of Clinical Pathology 2015, 144: a064-a064. DOI: 10.1093/ajcp/144.suppl2.064.
  • 78: The Utility of CD16 B73.1 in the Flow Cytometric Evaluation of ImmunodeficiencyMuch M, Tormey C, Siddon A. 78: The Utility of CD16 B73.1 in the Flow Cytometric Evaluation of Immunodeficiency American Journal Of Clinical Pathology 2015, 143: a047-a047. DOI: 10.1093/ajcp/143.suppl1.048.
  • Chronic Inflammatory Autoimmune Disorders Are a Risk Factor for Blood Group Alloimmunization in Transfused PatientsRyder A, Hendrickson J, Tormey C. Chronic Inflammatory Autoimmune Disorders Are a Risk Factor for Blood Group Alloimmunization in Transfused Patients Blood 2014, 124: 4294-4294. DOI: 10.1182/blood.v124.21.4294.4294.
  • Polyclonal Anti-Kel (KELGAM) Prevents Alloimmunization to Transfused Kel RBCs in a Murine ModelStowell S, Arthur C, Girard-Pierce K, Sullivan H, Santhanakrishnan M, Natarajan P, Tormey C, Zimring J, Hendrickson J. Polyclonal Anti-Kel (KELGAM) Prevents Alloimmunization to Transfused Kel RBCs in a Murine Model Blood 2014, 124: 758-758. DOI: 10.1182/blood.v124.21.758.758.
  • Modeling Gas Exchange During Platelet StorageTorres R, Tormey C. Modeling Gas Exchange During Platelet Storage American Journal Of Clinical Pathology 2014, 142: a006-a006. DOI: 10.1093/ajcp/142.suppl1.006.
  • Lupus Anticoagulant Testing: Analysis of Discrepant Results and Preanalytical PitfallsChandler J, Rinder H, Torres R, Tormey C. Lupus Anticoagulant Testing: Analysis of Discrepant Results and Preanalytical Pitfalls American Journal Of Clinical Pathology 2014, 142: a080-a080. DOI: 10.1093/ajcp/142.suppl1.080.
  • The RBC as a Target of DamageHendrickson J, Tormey C. The RBC as a Target of Damage 2014, 3068-3080. DOI: 10.1016/b978-0-12-386456-7.06203-1.
  • Hematology in Clinical PathologyTorres R, Tormey C, Smith B. Hematology in Clinical Pathology 2014, 3269-3286. DOI: 10.1016/b978-0-12-386456-7.06305-x.
  • Use of B Cell Gene Rearrangement Studies to Establish Clonality in Cases of Nonproducer Nonsecretory Multiple MyelomaSiddon A, Torres R, Tormey C. Use of B Cell Gene Rearrangement Studies to Establish Clonality in Cases of Nonproducer Nonsecretory Multiple Myeloma American Journal Of Clinical Pathology 2013, 140: a220-a220. DOI: 10.1093/ajcp/140.suppl1.220.
  • Assessing Compliance With Informed Consent for Blood Product TransfusionTormey C, Sekol J. Assessing Compliance With Informed Consent for Blood Product Transfusion American Journal Of Clinical Pathology 2013, 140: a034-a034. DOI: 10.1093/ajcp/140.suppl1.034.
  • Development of a Murine Model of Weak Kel: Similarities to Weak Rh(D)Hendrickson J, Smith N, Girard-Pierce K, Tormey C, Henry K, Zimring J, Stowell S. Development of a Murine Model of Weak Kel: Similarities to Weak Rh(D) Blood 2012, 120: 842-842. DOI: 10.1182/blood.v120.21.842.842.
  • Diagnosis, Treatment, and Reporting of Adverse Effects of TransfusionTorres R, Kenney B, Tormey C. Diagnosis, Treatment, and Reporting of Adverse Effects of Transfusion Lab Medicine 2012, 43: 217-231. DOI: 10.1309/lm3naabjjk1hnyfu.
  • 351 Blood group antigen alloimmunization in patients with myelodysplastic syndromesTorres R, Eisenbarth S, Tormey C. 351 Blood group antigen alloimmunization in patients with myelodysplastic syndromes Leukemia Research 2011, 35: s140-s141. DOI: 10.1016/s0145-2126(11)70353-8.
  • Chapter 53 Disorders of Hemostasis BleedingTormey C, Rinder H. Chapter 53 Disorders of Hemostasis Bleeding 2010, 564-579. DOI: 10.1016/b978-1-4160-6109-0.00053-8.
  • A Polymorphism in the XPNPEP2 Gene Is Associated with the Development of Hypotensive Transfusion Reactions without ACE Inhibitors.Hui Y, Tormey C, Wu Y. A Polymorphism in the XPNPEP2 Gene Is Associated with the Development of Hypotensive Transfusion Reactions without ACE Inhibitors. Blood 2009, 114: 3140-3140. DOI: 10.1182/blood.v114.22.3140.3140.
  • Transfusion Support for the Oncology PatientTormey C, Snyder E. Transfusion Support for the Oncology Patient 2009, 482-497. DOI: 10.1002/9781444303513.ch31.